February 19, 2026
Arcus Biosciences CEO Terry Rosen on building a discovery-first biotech, its differentiated pipeline, and its plan to win in oncology.
February 16, 2026
Memo Therapeutics CEO Erik van den Berg on tackling BK virus in transplant patients with a potent antibody, impressive Phase 2 data, & platform tech.
February 12, 2026
Biotech leader Declan Doogan shares his journey from big pharma to startups & Causeway's groundbreaking microRNA treatment for tendon disease.
February 11, 2026
Rectify Pharma CEO Raj Devraj on the art of drug hunting, de-risking breakthrough science, strategic team building, and navigating fundraising.
February 3, 2026
Enara Bio CEO Kevin Pojasek on pioneering 'dark antigen' cancer targets, building a people-first culture, and the next frontier for solid tumors.
January 22, 2026
Delpha Therapeutics CEO Kevin Marks discusses 'activation lethality,' a novel cancer therapy, the scientist-to-CEO journey, and building a culture-first biotech.
January 15, 2026
AeroRx CEO Ahmet Tutuncu discusses a $21M Series A for a novel nebulized dual bronchodilator targeting severe COPD patients unable to use inhalers.
January 5, 2026
Resolution Therapeutics CEO Amir Hefni discusses a novel macrophage cell therapy for liver disease, now in a Phase 1/2 trial with data due in 2026.
December 19, 2025
BridgeBio executive Justin To on pioneering genetic disease treatments with a decentralized R&D model, turning academic science into patient impact.
SpliceBio CEO Miquel Vila-Perello discusses their protein splicing platform, tackling Stargardt disease, and navigating biotech fundraising.
December 16, 2025
Beacon Therapeutics CEO Lance Baldo on advancing a Phase 3 gene therapy for blindness, the advantages of ocular treatments, and global leadership.
December 15, 2025
Luba Greenwood, CEO of Gallop Oncology, discusses biotech leadership, disciplined fundraising, and the essential CEO skills for today's market.
December 9, 2025
CDR Life CEO Christian Leisner shares insights on building a biotech, pioneering T-cell engagers, and leveraging Switzerland's unique ecosystem.
